Experimental cocktail aims to neutralize deadly grain fumigant poisoning
NCT ID NCT07451561
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This trial tests a combination of three drugs—glucose-insulin-potassium (GIK), hydrocortisone, and sevelamer—in 74 people with severe aluminum phosphide poisoning. The goal is to see if this mix can lower death rates by countering shock and directly neutralizing the toxic gas. Participants must be between 12 and 60 years old, in shock, and treated within 12 hours of ingestion.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Glucose-insulin-potassium (GIK) infusion, intravenous hydrocortisone, and oral sevelamer
What this could lead to
If it works, this could point toward an effective treatment for aluminum phosphide poisoning, which currently has no antidote.
What could go wrong
This is a small, early-stage trial with only 74 participants, so results may not apply widely. The combination therapy also carries risks like blood sugar and potassium imbalances.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE ALUMINUM PHOSPHIDE POISONED CASES are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Locations
-
Sohag university hospital
Sohag, 82611, Egypt
Contact